T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs

PHASE3CompletedINTERVENTIONAL
Enrollment

525

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Enfuvirtide

Trial Locations (37)

Unknown

Carlton Clinic, Carlton

Holdsworth House General Practice, Darlinghurst

Saint Vincent's Hosp, Darlinghurst

Royal Brisbane Hosp, Herston

Alfred Hosp, Prahan

Prahran Market Clinic, South Yarra

Taylors Square Clinic, Sydney

Inst of Tropical Medicine, Antwerp

CHU Saint Pierre, Brussels

UZ Gasthuisberg, Leuven

Rheinische Friedrich Wilhelms Universitaet Medizinische, Bonn

Klinikum Der Johann Wolfgang Goethe Universitat, Frankfurt

Allgemeines Krankenhaus St Georg, Hamburg

Universitatskrankenhaus Eppendorf, Hamburg

UO Malattie Infettive, Florence

Clinica Malattie Infettive, Milan

Ospedale Amedeo di Savoia, Torino

Natac Med Centre, Amsterdam

Univ Medical Center Utrecht, CX Utrecht

Hospital Germans Trias I Pujol, Barcelona

Hosp La Paz, Madrid

Hospital General Universitario, Valencia

University Hospital Mas, Malmo

Karolinska Hospital, Stockholm

Venhalsan Soder Hosp, Stockholm

Univ Hosp Basel / Med Outpatient Dept, Basel

Hopital cantonal / Div des maladies infectieuses, Geneva

CHUV, Lausanne

Universitatsspital Zurich, Zurich

Brighton Gen Hosp, Brighton

Western Gen Hosp, Edinburgh

Royal Liverpool Univ Hosp, Liverpool

Chelsea and Westminster Hosp, London

King's College Hospital, London

Royal Free Hosp, London

Univ College London Med School, London

North Manchester Gen Hosp, Manchester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Trimeris

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY

NCT00021554 - T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs | Biotech Hunter | Biotech Hunter